Am J Psychiatry 158:266-269, February 2001
© 2001 American Psychiatric Association
Rehospitalization Rates of Chronically Ill Schizophrenic Patients Discharged on a Regimen of Risperidone, Olanzapine, or Conventional Antipsychotics
Jonathan Rabinowitz, Ph.D.,
Pesach Lichtenberg, M.D.,
Zeev Kaplan, M.D.,
Mordechai Mark, M.D.,
Danielle Nahon, M.A., and
Michael Davidson, M.D.
OBJECTIVE: The purpose of this study was to compare the rehospitalization rates of patients discharged from the hospital while being treated with risperidone, olanzapine, or conventional antipsychotics. METHOD: By using Israel’s National Psychiatric Hospitalization Case Registry, rehospitalization status was monitored for all patients with schizophrenia who were discharged from any inpatient psychiatric facility in Israel while taking risperidone (N=268) or olanzapine (N=313) between Jan. 1, 1998, and Dec. 31, 1998, and a group of patients discharged during that time who were treated with conventional antipsychotics (N=458). Time to readmission over the course of 2 years was measured by the product-limit (Kaplan-Meier) formula. RESULTS: The readmission rate for patients discharged while taking conventional antipsychotics was higher than the rates for patients treated with either risperidone or olanzapine. At 24 months, 67% of the risperidone-treated patients and 69% of the olanzapine-treated patients remained in the community, as compared to 52% of the patients treated with conventional antipsychotics. CONCLUSIONS: This study suggests that the rehospitalization rates of patients taking the novel antipsychotics risperidone and olanzapine are not different from each other and are considerably lower than the rate for patients treated with conventional antipsychotics. The results confirm findings of previous studies suggesting that the levels of overall effectiveness of risperidone and olanzapine are not very different and offers evidence that these drugs are more effective in preventing rehospitalization than conventional antipsychotic drugs.
This article has been cited by other articles:
|
|
|
|
 
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Herbeck, J. C. West, I. Ruditis, F. F. Duffy, D. J. Fitek, C. C. Bell, and L. R. Snowden
Variations in Use of Second-Generation Antipsychotic Medication by Race Among Adult Psychiatric Patients
Psychiatr Serv,
June 1, 2004;
55(6):
677 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G Liu, S. X Sun, D. B Christensen, and X. Luo
Cost Comparisons of Olanzapine and Risperidone in Treating Schizophrenia
Ann. Pharmacother.,
January 1, 2004;
38(1):
134 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Thieda, S. Beard, A. Richter, and J. Kane
An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia
Psychiatr Serv,
April 1, 2003;
54(4):
508 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dickey, S.-L. T. Normand, R. C. Hermann, S. V. Eisen, D. E. Cortes, P. D. Cleary, and N. Ware
Guideline Recommendations for Treatment of Schizophrenia: The Impact of Managed Care
Arch Gen Psychiatry,
April 1, 2003;
60(4):
340 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Patel, P. G. Dorson, N. Edwards, S. Mendelson, and M. L. Crismon
One-Year Rehospitalization Rates of Patients Discharged on Atypical Versus Conventional Antipsychotics
Psychiatr Serv,
July 1, 2002;
53(7):
891 - 893.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
